Literature DB >> 3127830

Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation.

E De Plaen1, C Lurquin, A Van Pel, B Mariamé, J P Szikora, T Wölfel, C Sibille, P Chomez, T Boon.   

Abstract

Mutagen treatment of mouse P815 tumor cells produces tum- variants that are rejected by syngeneic mice because these variants express new surface antigens. These "tum- antigens" are recognized by cytolytic T lymphocytes but induce no detectable antibody response. Transfection of P815 cell line P1.HTR with DNA of tum- variant P91 yielded transfectants expressing tum- antigen P91A. They were detected by their ability to stimulate proliferation of cytolytic T lymphocytes [Wölfel, T., Van Pel, A., De Plaen, E., Lurquin, C., Maryanski, J. L. & Boon, T. (1987) Immunogenetics 26, 178-187]. A cosmid library of a cell line expressing antigen P91A was transfected into P1.HTR. Transfectants expressing the antigen were obtained. By packaging directly the DNA of a transfectant with lambda phage extracts, we obtained a small cosmid population containing as major component a cosmid that transferred the expression of P91A. The assay of various restriction fragments of this cosmid led to the isolation of an 800-base-pair fragment containing the P91A sequence required for transfection. Comparison with a homologous cDNA showed that this fragment contained only one of the several exons of the P91A gene. The normal and the tum- forms of the gene differ by one nucleotide located in this 137-base-pair exon. The essential role of this mutation, which produces an amino acid change, was confirmed by site-directed mutagenesis. No significant sequence similarity was found between the 800-base-pair fragment and any recorded gene.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3127830      PMCID: PMC279973          DOI: 10.1073/pnas.85.7.2274

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

2.  Rapid and sensitive protein similarity searches.

Authors:  D J Lipman; W R Pearson
Journal:  Science       Date:  1985-03-22       Impact factor: 47.728

3.  Selection of highly transfectable variant from mouse mastocytoma P815.

Authors:  A Van Pel; E De Plaen; T Boon
Journal:  Somat Cell Mol Genet       Date:  1985-09

Review 4.  Antigenic tumor cell variants obtained with mutagens.

Authors:  T Boon
Journal:  Adv Cancer Res       Date:  1983       Impact factor: 6.242

5.  Double cos site vectors: simplified cosmid cloning.

Authors:  P F Bates; R A Swift
Journal:  Gene       Date:  1983-12       Impact factor: 3.688

6.  Isolation of the gene encoding the human T-lymphocyte differentiation antigen Leu-2 (T8) by gene transfer and cDNA subtraction.

Authors:  P Kavathas; V P Sukhatme; L A Herzenberg; J R Parnes
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

7.  Construction of a fusion gene that confers resistance against hygromycin B to mammalian cells in culture.

Authors:  H U Bernard; G Krämmer; W G Röwekamp
Journal:  Exp Cell Res       Date:  1985-05       Impact factor: 3.905

8.  DNA-mediated transfer of human melanoma cell surface glycoprotein gp130: identification of transfectants by erythrocyte rosetting.

Authors:  A P Albino; L H Graf; R R Kantor; W McLean; S Silagi; L J Old
Journal:  Mol Cell Biol       Date:  1985-04       Impact factor: 4.272

9.  Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VI. Occasional escape from host rejection due to antigen-loss secondary variants.

Authors:  J L Maryanski; M Marchand; C Uyttenhove; T Boon
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

10.  Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination.

Authors:  O Smithies; R G Gregg; S S Boggs; M A Koralewski; R S Kucherlapati
Journal:  Nature       Date:  1985 Sep 19-25       Impact factor: 49.962

View more
  77 in total

1.  A new approach to the cloning of genes encoding T-cell epitopes.

Authors:  D M Scott; P J Dyson; E Simpson
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

Review 2.  Role of class I molecules of the major histocompatibility complex in cytotoxic T-cell function in health and disease.

Authors:  A J McMichael
Journal:  Springer Semin Immunopathol       Date:  1992

3.  Compartmentalized MHC class I antigen processing enhances immunosurveillance by circumventing the law of mass action.

Authors:  Avital Lev; Michael F Princiotta; Damian Zanker; Kazuyo Takeda; James S Gibbs; Chiharu Kumagai; Elizabeth Waffarn; Brian P Dolan; Anne Burgevin; Peter Van Endert; Weisan Chen; Jack R Bennink; Jonathan W Yewdell
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

Review 4.  'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations.

Authors:  Eric Tran; Paul F Robbins; Steven A Rosenberg
Journal:  Nat Immunol       Date:  2017-02-15       Impact factor: 25.606

Review 5.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Authors:  Pierre G Coulie; Benoît J Van den Eynde; Pierre van der Bruggen; Thierry Boon
Journal:  Nat Rev Cancer       Date:  2014-02       Impact factor: 60.716

Review 6.  Immunotherapy I: Cyclosine gene transfer strategies.

Authors:  M P Colombo; G Forni
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

Review 7.  Regulatory mechanisms of antitumor T cell responses in the tumor-bearing state.

Authors:  H Fujiwara; T Hamaoka
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

8.  T cell-recognized antigenic peptides derived from the cellular genome are not protein degradation products but can be generated directly by transcription and translation of short subgenic regions. A hypothesis.

Authors:  T Boon; A Van Pel
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

Review 9.  Targeting neoantigens to augment antitumour immunity.

Authors:  Mark Yarchoan; Burles A Johnson; Eric R Lutz; Daniel A Laheru; Elizabeth M Jaffee
Journal:  Nat Rev Cancer       Date:  2017-02-24       Impact factor: 60.716

10.  Efficient expression of tum- antigen P91A by transfected subgenic fragments.

Authors:  P Chomez; E De Plaen; A Van Pel; C De Smet; J P Szikora; C Lurquin; A M Lebacq-Verheyden; T Boon
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.